Beacon Capital Management LLC Increases Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Beacon Capital Management LLC raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 242 shares of the medical research company’s stock after buying an additional 20 shares during the quarter. Beacon Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $126,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Savant Capital LLC boosted its holdings in Thermo Fisher Scientific by 0.5% during the fourth quarter. Savant Capital LLC now owns 3,627 shares of the medical research company’s stock valued at $1,997,000 after acquiring an additional 18 shares during the period. Connecticut Wealth Management LLC increased its position in Thermo Fisher Scientific by 3.0% in the 1st quarter. Connecticut Wealth Management LLC now owns 614 shares of the medical research company’s stock worth $354,000 after buying an additional 18 shares during the period. Sage Rhino Capital LLC boosted its position in shares of Thermo Fisher Scientific by 2.6% in the first quarter. Sage Rhino Capital LLC now owns 723 shares of the medical research company’s stock valued at $417,000 after acquiring an additional 18 shares during the period. 1776 Wealth LLC grew its stake in shares of Thermo Fisher Scientific by 2.4% in the fourth quarter. 1776 Wealth LLC now owns 799 shares of the medical research company’s stock worth $440,000 after acquiring an additional 19 shares during the last quarter. Finally, Crumly & Associates Inc. raised its stake in Thermo Fisher Scientific by 1.5% during the 1st quarter. Crumly & Associates Inc. now owns 1,274 shares of the medical research company’s stock valued at $734,000 after purchasing an additional 19 shares during the last quarter. 87.06% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

NYSE TMO traded down $1.42 during trading hours on Tuesday, reaching $506.31. 196,556 shares of the company’s stock were exchanged, compared to its average volume of 1,492,749. The firm has a fifty day moving average of $540.37 and a 200-day moving average of $541.53. The company has a current ratio of 1.42, a quick ratio of 1.02 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a one year low of $475.77 and a one year high of $609.85. The stock has a market cap of $195.41 billion, a PE ratio of 34.72, a price-to-earnings-growth ratio of 2.43 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 26th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.43 by ($0.28). Thermo Fisher Scientific had a net margin of 13.14% and a return on equity of 18.59%. The business had revenue of $10.69 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same period in the prior year, the firm earned $5.51 earnings per share. The business’s quarterly revenue was down 2.6% compared to the same quarter last year. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 22.37 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 13th. Stockholders of record on Friday, September 15th will be paid a $0.35 dividend. This represents a $1.40 annualized dividend and a dividend yield of 0.28%. The ex-dividend date is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.57%.

Analysts Set New Price Targets

TMO has been the topic of several research reports. Credit Suisse Group upgraded shares of Thermo Fisher Scientific from a “neutral” rating to an “outperform” rating and set a $620.00 price objective on the stock in a report on Thursday, July 13th. Citigroup started coverage on Thermo Fisher Scientific in a report on Wednesday, September 6th. They set a “buy” rating and a $625.00 price objective on the stock. Raymond James raised their target price on Thermo Fisher Scientific from $595.00 to $630.00 and gave the stock an “outperform” rating in a research report on Friday, July 28th. KeyCorp dropped their price objective on shares of Thermo Fisher Scientific from $710.00 to $640.00 in a research note on Thursday, May 25th. Finally, StockNews.com upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Friday. One analyst has rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $631.71.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CFO Stephen Williamson sold 14,100 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $550.00, for a total transaction of $7,755,000.00. Following the transaction, the chief financial officer now owns 27,393 shares of the company’s stock, valued at approximately $15,066,150. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Stephen Williamson sold 14,100 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $550.00, for a total value of $7,755,000.00. Following the completion of the transaction, the chief financial officer now directly owns 27,393 shares in the company, valued at approximately $15,066,150. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $549.00, for a total transaction of $5,490,000.00. Following the sale, the chief executive officer now owns 141,330 shares in the company, valued at $77,590,170. The disclosure for this sale can be found here. In the last 90 days, insiders sold 28,700 shares of company stock worth $15,799,270. Insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.